Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8LYSB)

• Drug Name: Triazine Drug Info
• Synonyms: Anilazine; DYRENE; Zinochlor; Anilazin; Kemate; 101-05-3; Bortrysan; Triazin; Triasyn; Triasym; Direz; Dyrene 50W; Aniyaline; Dyrene Flussig; Triazine (pesticide); 4,6-Dichloro-N-(2-chlorophenyl)-1,3,5-triazin-2-amine; 2,4-Dichloro-6-(o-chloroanilino)-s-triazine; NCI-C08684; (o-Chloroanilino)dichlorotriazine; Triazine (VAN); NSC 3851; Caswell No. 302; 2,4-Dichloro-6-(2-chloroanilino)-1,3,5-triazine; Dairene; Anilazine [BSI:ISO]; ENT 26,058; 1,3,5-Triazin-2-amine, 4,6-dichloro-N-(2-chlorophenyl)-; UNII-C6E8Y03ZJN; B-622; CCRIS 43

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 123047
  ChEBI ID: CHEBI:38058
  CAS Number: CAS 12654-97-6
  TTD Drug ID: DM8LYSB

Molecule-Related Drug Atlas

Drug(s) Targeting Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Artemisinin	DMOY7W3	Malaria	1F40-1F45	Approved	[4]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[5]
Teriflunomide	DMQ2FKJ	Hyperlipidaemia	5C80	Approved	[6]
Atovaquone	DMY4UMW	Fungal infection	1F29-1F2F	Approved	[7]
Avastin+/-Tarceva	DMA86FL	Non-small-cell lung cancer	2C25.Y	Phase 3	[1]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[8]
B-Octylglucoside	DMMO75G	Discovery agent	N.A.	Investigative	[8]
Orotate	DMMB29S	Discovery agent	N.A.	Investigative	[9]
Lauryl Dimethylamine-N-Oxide	DM3W2OE	Discovery agent	N.A.	Investigative	[8]
1,4-Naphthoquinone	DMTCMH7	Discovery agent	N.A.	Investigative	[1]

Drug(s) Affected By NAD(P)H dehydrogenase 1 (NQO1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[10]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[11]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[12]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[13]
TECFIDERA	DM2OVDT	Multiple sclerosis	8A40	Approved	[14]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[15]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[16]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[17]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[18]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[19]

Drug(s) Affected By Cytochrome P450 1A2 (CYP1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[20]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[20]
Etoricoxib	DM6A4NW	Rheumatoid arthritis	FA20	Approved	[20]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[21]
Hesperetin	DMKER83	High blood cholesterol level	5C80.00	Approved	[22]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[23]
Nifedipine	DMSVOZT	Angina pectoris	BA40	Approved	[24]
Zileuton	DMVRIC2	Allergic asthma	CA23.0	Approved	[25]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[26]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[27]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)	TT3PQ2Y	PYRD_PLAF7	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cytochrome P450 1A2 (CYP1A2)	OTLLBX48	CP1A2_HUMAN	Regulation of Drug Effects	[2]
NAD(P)H dehydrogenase 1 (NQO1)	OTZGGIVK	NQO1_HUMAN	Gene/Protein Processing	[3]

References

• [1] Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76.
• [2] Identification of enzymes involved in the metabolism of atrazine, terbuthylazine, ametryne, and terbutryne in human liver microsomes. Chem Res Toxicol. 1997 Sep;10(9):1037-44. doi: 10.1021/tx970081l.
• [3] NRH:quinone oxidoreductase2 (NQO2). Chem Biol Interact. 2000 Dec 1;129(1-2):99-112.
• [4] The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
• [5] Identification and characterization of potential new therapeutic targets in inflammatory and autoimmune diseases. Eur J Biochem. 1999 Dec;266(3):1184-91.
• [6] Expression and characterization of E. coli-produced soluble, functional human dihydroorotate dehydrogenase: a potential target for immunosuppression. J Mol Microbiol Biotechnol. 1999 Aug;1(1):183-8.
• [7] Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain. Protein Sci. 2004 Apr;13(4):1031-42.
• [8] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [9] Antimalarial activity of orotate analogs that inhibit dihydroorotase and dihydroorotate dehydrogenase. Biochem Pharmacol. 1992 Mar 17;43(6):1295-301.
• [10] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [11] Functional cardiotoxicity assessment of cosmetic compounds using human-induced pluripotent stem cell-derived cardiomyocytes. Arch Toxicol. 2018 Jan;92(1):371-381.
• [12] Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
• [13] Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
• [14] Enhanced cytotoxicity of bioreductive antitumor agents with dimethyl fumarate in human glioblastoma cells. Anticancer Drugs. 2005 Feb;16(2):167-74.
• [15] Growth-suppressive effect of non-steroidal anti-inflammatory drugs on 11 colon-cancer cell lines and fluorescence differential display of genes whose expression is influenced by sulindac. Int J Cancer. 2000 Dec 15;88(6):873-80. doi: 10.1002/1097-0215(20001215)88:6<873::aid-ijc6>3.0.co;2-b.
• [16] Simvastatin protects dopaminergic neurons against MPP+-induced oxidative stress and regulates the endogenous anti-oxidant system through ERK. Cell Physiol Biochem. 2018;51(4):1957-1968.
• [17] P450 3A-catalyzed O-dealkylation of lapatinib induces mitochondrial stress and activates Nrf2. Chem Res Toxicol. 2016 May 16;29(5):784-96.
• [18] Induction of human NAD(P)H:quinone oxidoreductase (NQO1) gene expression by the flavonol quercetin. Toxicol Lett. 2001 Feb 3;119(1):49-57.
• [19] Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
• [20] In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):157-65.
• [21] Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
• [22] Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36.
• [23] Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
• [24] Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
• [25] Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2003 Nov;31(11):1352-60.
• [26] Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem. 2005 Jun 2;48(11):3808-15.
• [27] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.